Flag of the European Union EU Clinical Trials Register Help

Clinical trials for eudract

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    227 result(s) found for: eudract. Displaying page 4 of 12.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-020482-24 Sponsor Protocol Number: 1 Start Date*: 2014-10-23
    Sponsor Name:Department of Endocrinology, Sahlgrenska University Hospital
    Full Title: Ga-68-DOTATOC -PET in the management of pituitary tumours (PA) and Thyroid associated ophtalmopathy (TAO)
    Medical condition: In this trial with Ga-68 DOTATOC two groupd of patients will be investigated - patients with pituitary adenoma (PA) and patients with thyroid associateed ophtalmopathy (TAO). As the eye muscles and...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-000509-58 Sponsor Protocol Number: RC31/18/0472 Start Date*: 2019-10-08
    Sponsor Name:CHU de Toulouse
    Full Title: Cerebral hemodynamic optimization by milrinone for the prevention of delayed cerebral ischemia in severe subarachnoid hemorrhages
    Medical condition: delayed cerebral ischemia in severe subarachnoid hemorrhages
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10019587 Hemorrhage subarachnoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001611-50 Sponsor Protocol Number: S67072 Start Date*: 2022-11-15
    Sponsor Name:UZ Leuven
    Full Title: Patient reported efficacy of intranasal lysine-aspirin in controlling NSAID-exacerbated respiratory disease
    Medical condition: Aspirin-Exacerbated Respiratory Disease (AERD) in patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
    Disease: Version SOC Term Classification Code Term Level
    25.1 100000004855 10075084 Aspirin-exacerbated respiratory disease LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005657-12 Sponsor Protocol Number: HUS277/03/2015 Start Date*: 2016-01-21
    Sponsor Name:HUS - Naistentautien ja synnytysten tulosyksikkö
    Full Title: Pain an medical abortion -Predicting factors of pain and optimal pain management among teenaged women compared to adult women
    Medical condition: Pain during Medical termination of pregnancy
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003959-11 Sponsor Protocol Number: 1703001 Start Date*: 2020-05-25
    Sponsor Name:Vestre Viken Trust
    Full Title: MUscle Side-Effects of atorvastatin in coronary patients (MUSE) follow-up study
    Medical condition: Coronary heart disease patients With perceived statin Associated muscle symptoms or statin discontinuaton due to muscle symptoms
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000664-85 Sponsor Protocol Number: 8VWF03 Start Date*: 2006-12-19
    Sponsor Name:Bio Products Laboratory
    Full Title: An Open Multi-centre Study to Investigate the Safety and Efficacy of OPTIVATE®, a High Purity, Dual Inactivated Factor VIII and von Willebrand Factor Concentrate, in Patients with von Willebrand Di...
    Medical condition: von Willebrand disease
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000321-31 Sponsor Protocol Number: rhLAMAN-09 Start Date*: 2013-06-07
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A multi-center, un-controlled, open-labeled trial of the long-term safety of Velmanase Alfa aftercare treatment of subjects with alpha-Mannosidosis whom previously participated in Velmanase Alfa - ...
    Medical condition: Treatement of Alpha-Mannosidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10032658 Other specified disorders of carbohydrate transport and metabolism LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-002687-27 Sponsor Protocol Number: I6T-MC-AMAX Start Date*: 2020-04-28
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Crohn's Disease
    Medical condition: Crohn´s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) SK (Trial now transitioned) LV (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) LT (Trial now transitioned) IT (Trial now transitioned) DK (Prematurely Ended) HR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000979-17 Sponsor Protocol Number: rhLAMAN-05 Start Date*: 2012-12-17
    Sponsor Name:Zymenex A/S
    Full Title: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial, Investigating the Efficacy and Safety of Repeated Lamazym Treatment of Subjects with alpha-Mannosidosis
    Medical condition: Treatement of Alpha-Mannosidosis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) BE (Completed) ES (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001603-37 Sponsor Protocol Number: AC-055G203 Start Date*: 2019-07-16
    Sponsor Name:ACTELION Pharmaceuticals Ltd
    Full Title: A long-term, multicenter, single-arm, open-label extension of the SERENADE study, to assess the safety and efficacy of macitentan in subjects with heart failure with preserved ejection fraction and...
    Medical condition: Heart failure with preserved ejection fraction and pulmonary vascular disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10076396 Heart failure with preserved ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) DE (Prematurely Ended) HU (Prematurely Ended) DK (Prematurely Ended) SE (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003987-22 Sponsor Protocol Number: GT-ORACLE Start Date*: 2022-11-08
    Sponsor Name:Gyroscope Therapeutics Ltd.
    Full Title: ORACLE: A long-term follow-up study to evaluate the safety of GT005 in participants with geographic atrophy, secondary to age-related macular degeneration treated in a Gyroscope-sponsored anteceden...
    Medical condition: Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in participants already treated with GT005 in the GT-005-1 (FOCUS), GT-005-02 (EXPLORE) and GT005-03 (HORIZON) antecedent...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10075719 Atrophic age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) IE (Prematurely Ended) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023953-12 Sponsor Protocol Number: DFI12712 Start Date*: 2013-12-16
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 2, Multi-Center, Randomized, Open-Label, Repeat Dose, Dose-Comparison Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Human Acid Sphingomyelinase in Patients Wit...
    Medical condition: Patients with acid sphingomyelinase deficiency (Niemann-Pick Type B disease)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10041515 Sphingomyelin lipidosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-007669-20 Sponsor Protocol Number: 37822681SCH2003 Start Date*: 2008-08-18
    Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
    Full Title: A Double-Blind, Multiple Dose Titration Study to Investigate the Safety, Tolerability and Pharmacokinetics of Once Daily and Twice Daily Doses of JNJ-37822681 in Male and Female Patients With Stabl...
    Medical condition: Schizophrenia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) SE (Prematurely Ended) BE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2004-001814-14 Sponsor Protocol Number: ABD101684 Start Date*: 2005-11-21
    Sponsor Name:GlaxoSmithKline R&D Limited
    Full Title: A Double-Blind, Placebo-Controlled, Multicenter Phase IIb Extension Study to Evaluate the Safety and Efficacy of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunc...
    Medical condition: Opioid-Induced Bowel Dysfunction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FI (Prematurely Ended) IE (Completed) CZ (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-000411-14 Sponsor Protocol Number: 6639 Start Date*: 2014-07-17
    Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: A randomised double blind dose non-inferiority trial of a daily dose of 600mg versus 300mg versus 100mg of enteric coated aspirin as a cancer preventive in carriers of a germline pathological misma...
    Medical condition: Lynch Syndrome also known as HNPCC (non hereditary non polyposis colorectal cancer).
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004850 10051981 Lynch syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FI (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-007023-26 Sponsor Protocol Number: A3921044 Start Date*: 2009-05-18
    Sponsor Name:Pfizer Inc.
    Full Title: PHASE 3 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE
    Medical condition: CP 690,550 is being studied as a disease modifying antirheumatic drug for the treatment of moderate to severe active rheumatoid arthritis in adults.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GR (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-000936-28 Sponsor Protocol Number: PMR-EC-1105 Start Date*: 2006-09-14
    Sponsor Name:Astellas Pharma Europe Limited
    Full Title: A MULTICENTER, OPEN, SINGLE SEQUENCE CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN STABLE LIVER TRANSPLANT PAT...
    Medical condition: Stable, adult liver transplant recipients (≥ 12 months post transplant) who are currently treated with Prograf.
    Disease: Version SOC Term Classification Code Term Level
    7.0 10024716 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Completed) ES (Completed) FR (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004322-24 Sponsor Protocol Number: OV-1012 Start Date*: 2008-03-17
    Sponsor Name:Lundbeck Inc
    Full Title: Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome.
    Medical condition: Lennox-Gastaut Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10048816 Lennox-Gastaut syndrome LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-006041-16 Sponsor Protocol Number: NK-104-310 Start Date*: 2006-06-30
    Sponsor Name:Kowa Research Europe Ltd.
    Full Title: DOUBLE-BLIND FOLLOW-ON STUDY OF PITAVASTATIN (4 MG) VERSUS ATORVASTATIN (20 MG AND 40 MG), WITH A SINGLE BLIND EXTENSION OF TREATMENT IN PATIENTS WITH TYPE II DIABETES MELLITUS AND COMBINED DYSLIPI...
    Medical condition: Combined Dyslipidemia and Type II Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    8.1 10058110 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006300-27 Sponsor Protocol Number: MC-ASP.6/INF Start Date*: 2009-08-12
    Sponsor Name:medac Gesellschaft für klinische Spezialpräparate mbH
    Full Title: Efficacy and safety of recombinant asparaginase in infants (< 1 year) with previously untreated acute lymphoblastic leukaemia - Phase II Clinical Trial -
    Medical condition: Acute lymphoblastic leukaemia (ALL) is a clonal disease resulting from genetic mutations and transformation of a single early progenitor lymphoid cell. Uncontrolled expansion of leukaemic blasts in...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 26 12:45:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA